Transit Scientific has announced the close of its Series A financing round. The round was led by a large multinational investor and joined by previous seed investors.
Transit Scientific achieved US Food and Drug Administration (FDA) clearances and multicentre, multi-user, safe-patient-use of its XO Score angioplasty scoring-cutting platform and separate XO Cross 0.014” and 0.035” microcatheter platform in late 2020.
“XO Score successfully dilated multiple lesions that were resistant to standard or high-pressure balloon angioplasty during our 1st patient uses in haemodialysis fistulas,” said Jeffrey Hoggard (Raleigh Access Center, Raleigh, USA). “It was particularly beneficial to be able to deploy the XO Score device with a standard percutaneous transluminal angioplasty (PTA) balloon in the juxta-anastomotic position and dilate the lesion at low and controlled inflation pressure.”
The XO Score is a novel sheath that converts regular angioplasty balloons into vessel prep scoring and cutting systems. The device is indicated for treatment of peripheral vascular stenosis including haemodialysis fistulas and grafts.
XO Score’s 22 individual scoring and cutting struts rotate 90 degrees to score and cut upon balloon inflation and then rotate 90 degrees back upon balloon deflation to facilitate balloon re-wrap. The technology also allows for infusion at the site of treatment.
“The XO Cross 014, 018, and 035 microcatheter platform adds new torque, pushability and catheter control,” said Richard Saxon (Tri-City Medical Center, Oceanside, USA. “We have used a 014 XO Cross to redirect the guidewire intraluminally while crossing a tibial artery chronic total occlusion (CTO). This would have been very difficult to achieve with other available technology.”
The XO Cross is a non-tapered exoskeleton based microcatheter technology designed to improve torque response, trackability, and control.
